The term ‘moonshot’ references the NASA moon missions of the 1960s, describing visionary, ambitious and innovative undertakings that redefined the boundaries of science and society. In recent times, it’s a phrase that the European Commission has used in the draft Horizon Europe 2028-2034 research initiative to describe building the Future Circular Collider or achieving commercial nuclear fusion.

What the phrase does not connote or encompass is the continuation of a status quo that fails to meet the needs of European citizens. As the Commission rightly points out, the EU is suffering from “an alarming failure to translate innovation into products or services”. This problem is particularly acute in the context of health research, an arena in which only a very small proportion of pre-clinical discoveries leads to actual advances for patients. This has been referred to as the “valley of death” in drug discovery, with an estimated 95 percent of promising drugs failing at clinical stage. A large percentage of this failure rate is a result of ‘animal models’ of human disease and toxicity that simply do not translate from the laboratory to human beings in the real world.

Achieving a high degree of translational relevance in biomedical models would be a true moonshot project, with its embrace of human biology as the new gold standard.

Achieving a high degree of translational relevance in biomedical models would be a true moonshot project, with its embrace of human biology as the new gold standard and a shift in research focus and funding to augment and enhance the existing toolbox of human-specific nonanimal methods (NAMs).

The EU stands on the threshold of such a moment: a €1 billion investment in a NAMs Moonshot Programme under Horizon Europe 2028-2034. Such a programme would represent a transformative, coordinated effort to accelerate the development, validation and adoption of more human-relevant research methods across the full innovation cycle, from discovery to deployment.

Europe’s current investment trajectory risks leaving it behind. Under the Choose Europe for Life Sciences strategy announced in July, the Commission pledged €10 billion annually through EU funding programs to position the EU as a global leader in health and life sciences. Yet only €50 million of that investment is earmarked for NAMs in 2026-27, not nearly enough to drive EU innovation or strengthen EU competitiveness.

By contrast, other global actors have not only recognised the strategic value of NAMs, but they have also put forward their money. The United States launched the NIH Complement-ARIE initiative in 2024, a 10-year, US$400 million programme to advance non-animal research methods, while the Netherlands established the Utrecht Ombion Centre for Animal-Free Biomedical Translation in 2025 with a €245 million investment. The current €50 million reserved for NAMs in the Commission’s strategy is not enough to get the job done.

With Horizon Europe 2028-2034 doubling its budget and foregrounding a set of visionary moonshot projects, there’s a window of opportunity for the EU to strengthen NAMs funding and secure a leadership role in human-relevant, next-generation life sciences. A structured, €1 billion EU-wide NAMs Moonshot Programme, grounded in the principles of scientific excellence, strategic autonomy and societal benefit is in close alignment with the European Research Area Action on NAMs, which focuses on validation, infrastructure, education and awareness.

With Horizon Europe 2028-2034 doubling its budget and foregrounding a set of visionary moonshot projects, there’s a window of opportunity for the EU to strengthen NAMs funding and secure a leadership role in human-relevant, next-generation life sciences.

To set a NAMs moonshot up for success, validation capacity (i.e., proving NAMs work reliably and accurately for their intended purpose) must be prioritised, along with solid infrastructure and training to build scientific credibility and technological scalability. Education and awareness initiatives are essential to develop a skilled workforce and sustain long-term adoption of these approaches. This investment would drive scientific innovation and strengthen EU competitiveness.

NAMs and human-centred experimental design must be embedded into educational curricula across disciplines. Inter- and transdisciplinary learning, integrating complex in vitro models, in silico tools and artificial intelligence (AI) will equip future researchers with the knowledge and skills needed to lead this scientific transition.

Europe should promote open-access research repositories, supported by AI technologies, to foster collaboration and knowledge sharing across sectors. Establishing a coordinated European NAMs Integration Hub would enhance alignment, build synergies and accelerate the uptake of human-relevant approaches across academia, industry, regulators and international partners. This would help avoid fragmentation while preventing the formation of new silos, enabling full knowledge sharing and cooperation.

Just as humankind once looked to the moon and saw immense possibilities, Europe must now be bold and invest in a future for health research that delivers for its citizens.

Social sciences and humanities must also play a central role in funded health research, ensuring fair partnerships with patient groups, regulators and other key interest holders. This will help align research with real-world needs, clarify intended outcomes and ensure the feasibility and social relevance of new approaches.

Just as humankind once looked to the moon and saw immense possibilities, Europe must now be bold and invest in a future for health research that delivers for its citizens. A €1 billion investment in human-specific NAMs would support improved patient outcomes, greener and more ethical research, and enhanced EU competitiveness. It would bring cutting-edge science closer to the lives it seeks to improve and place Europe in the driving seat of the next revolution in human health.

Disclaimer

POLITICAL ADVERTISEMENT

• The sponsor is Humane World for Animals
• The ultimate controlling entity is Humane World for Animals

More information here.